Open an account

Evolus

EOLS · NASDAQ

$7.37+$0.01 (+0.14%)TodayMarket closed ·
Prev close $7.36

About EOLS

Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. The company is headquartered in Newport Beach, California and currently employs 334 full-time employees. The company went IPO on 2018-02-08. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.

Employees
334
Headquarters
Newport Beach, California
Listed
Feb 8, 2018
Sector
Health Care
Industry
Pharmaceuticals
Website
evolus.com

EOLS key statistics

Market cap
486.79M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
726.51K
Volume
447.85K
Open price
$7.38
High today
$7.63
Low today
$7.34
52 Week high
$9.31
52 Week low
$3.86

Evolus (EOLS) at a glance

Evolus (EOLS) last traded at $7.37, with a market cap of 486.79M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $7.34 and $7.63. The current price is 0.5% above the day's low and 3.4% below its high.

Volume so far is 447.85K shares, below the average of 726.51K shares a day.

Over the past year Evolus has ranged from $3.86 to $9.31, and now sits 64% of the way up that range.

Evolus met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported $0.02 per share against an estimate of -$0.0352.

The average analyst price target is $15.30, 107.6% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

80%of 5 analyst ratings say Buy
  • Buy80.0%
  • Hold20.0%
  • Sell0.0%
Price target · 7 analystsAvg $15.30
Low
$12.12
Now
$7.37
High
$21.00

EOLS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 64.9% on average.

  1. Q3 FY24: reported -$0.16 per share against an estimate of -$0.0995
  2. Q4 FY24: reported $0.04 per share against an estimate of $0.0388
  3. Q1 FY25: reported -$0.15 per share against an estimate of -$0.1486
  4. Q2 FY25: reported -$0.23 per share against an estimate of -$0.1102
  5. Q3 FY25: reported -$0.11 per share against an estimate of -$0.176
  6. Q4 FY25: reported $0.05 per share against an estimate of $0.051
  7. Q1 FY26: reported -$0.05 per share against an estimate of -$0.1326
  8. Q2 FY26: reported $0.02 per share against an estimate of -$0.0352

EOLS news

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS

  • Press releaseBusiness Wire

    Evolus Expands Innovation Pipeline with Novel Injectable Hair Restoration Program

  • Press releaseBusiness Wire

    EOLS Investors with $100,000 in Losses Have Opportunity to Join Evolus, Inc. Fraud Investigation with SBS Law

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS

  • Vandana Singh

    Evolus Warned Over Misbranding in Social Media Promo for Frown Lines Drug

  • Press releaseBusiness Wire

    Evolus Launches Wings by Evolus, a New Charitable Platform to Mobilize Its Community in Support of Important Causes

Similar companies

Companies in the same industry as Evolus

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.